Collection and Distribution of Biospecimens for Novel Research

Sponsor
iSpecimen Inc (Industry)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05080907
Collaborator
(none)
100,000
10
101.6
10000
98.4

Study Details

Study Description

Brief Summary

iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively "research").

Detailed Description

The level of involvement for each network institution will vary based on the type of specimen to which they have access (e.g. biofluids, tissues and/or cells) and the category of collection (remnant specimens that were originally collected for clinical testing and/or specimens specifically collected for research) in accordance with the institution's elected preferences.

In most cases, potential participants will be identified and approached upon presenting for clinical care or recruited specifically for the study using outreach programs. If additional screening activities are required to determine eligibility criteria, the potential participant may be presented with the opportunity to participate in these activities as part of the study. These screening activities will be minimal risk in nature and are described further below. Should potential participants meet screening criteria, they may then be asked to provide biospecimens according to current research needs. Individual participants or groups of participants may be sought according to specific clinical, lifestyle, and/or demographic characteristics. The providers of these samples may be healthy participants or participants with a medical condition of interest to the research community but regardless, all specimens collected under this protocol (whether for screening purposes and for distribution to researchers) will qualify as minimal risk activities.

Biospecimens may be distributed to researchers at academic institutions, hospitals, clinical and government laboratories, and corporations including diagnostic, medical device, biopharmaceutical and biotechnology companies. The types of research studies and testing that may be performed using the biospecimens will be varied, and it is not possible to provide a description of all potential studies. Some researchers may perform genetic testing on the specimens, some may use the specimens to develop cell lines, and some may cryopreserve the specimens for many years, awaiting a research use. The specimens may also be used for educational purposes, such as training lab techs on the proper testing of samples or physicians on the proper reading of stained slides. The iSpecimen consent forms will indicate a broad scope of possible research and educational uses and activities.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
iSpecimen Network Protocol: Collection and Distribution of Remnant and Research Use Only Biospecimens for Novel Research
Actual Study Start Date :
Jul 15, 2016
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jan 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Collection of Biospecimens for Novel Research Uses [10 years]

    Repository of diseased and healthy tissue, blood derivatives and related biological specimens

Secondary Outcome Measures

  1. Number of subjects enrolled [10 years]

    Each subject will have contributed at least one biospecimen

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Year to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Individual is developmentally aged 7 years old and above for RUO collections (only)

  • Individual meets requirements of a current request for research materials from iSpecimen

  • If a blood collection will be performed as part of the screening process or RUO collection, the individual's health will be assessed by medical staff through medical record review, clinical exam, and/or the review of an updated medical history as provided by the participant

  • Individual has reviewed and signed a consent form for an RUO specimen collection if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent/guardian or Legally Authorized - Representative has reviewed and signed the consent form on their behalf.

  • Individual has reviewed and signed a consent form for remnant specimen usage in research if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent/guardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf

Exclusion Criteria:
  • Subjects that do not meet the inclusion criteria outlined above.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Central Alabama Birmingham Alabama United States 35005
2 Northern Alabama Huntsville Alabama United States 35649
3 Southern Alabama Area Mobile Alabama United States 36525
4 Central Alabama Montgomery Alabama United States 36043
5 Northern Arizona Flagstaff Arizona United States 86001
6 Central Arizona Phoenix Arizona United States 85001
7 South Central Arizona Tucson Arizona United States 85641
8 Western New York Buffalo New York United States 14221
9 Greater Philadelphia Area Philadelphia Pennsylvania United States 19102
10 Western Pennsylvania Pittsburgh Pennsylvania United States 15201

Sponsors and Collaborators

  • iSpecimen Inc

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
iSpecimen Inc
ClinicalTrials.gov Identifier:
NCT05080907
Other Study ID Numbers:
  • ISPC-160630-REM/RUO/
First Posted:
Oct 18, 2021
Last Update Posted:
Oct 18, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by iSpecimen Inc
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 18, 2021